Keywords

• Deucravacitinib Impurity
• 2222717-52-2
• C10H12N4O

Quick Details

• ProName: Deucravacitinib Impurity;2222717-52-2
• CasNo: 2222717-52-2
• Molecular Formula: C10H12N4O
• Appearance: White to off white powder
• Application: experiment research
• DeliveryTime: prompt delivery
• PackAge: Food bags, aluminum foil bags
• Port: Shenzhen/hongkong
• ProductionCapacity: 5000 Gram/Year
• Purity: 99%+ HPLC
• Storage: cool and dry
• Transportation: DHL,EMS,TNT,UPS,EMS,by air,by sea;
• LimitNum: 10 Milligram
• Moisture Content: 0.1%
• Impurity: 0.1%

Superiority

Advantages

• High-Purity Reference Standard：Confirmed by HPLC (≥99.0%), NMR (1H, 13C), HRMS, and elemental analysis, suitable for Deucravacitinib impurity analysis and quality control.

• Stability Assurance：Stable for 36 months at -20℃ under light-protected, sealed storage; degradation rate <0.3% in acetonitrile-water solution within 6 months.

Details

Deucravacitinib Impurity ; 2222717-52-2

Product Information

• Product Code：D084003

• English Name：Deucravacitinib Impurity 3

• English Alias：2-methoxy-3-(1-methyl-1H-1,2,4-triazol-5-yl)aniline

• CAS No.：2222717-52-2

• Molecular Formula：C??H??N?O

• Molecular Weight：204.23

Applications

• Quality Control Testing：Used for UPLC-MS/MS detection of Impurity 3 in Deucravacitinib API and formulations, controlling content to meet ICH Q3A standards (single impurity limit ≤0.1%).

• Process Optimization Research：Monitors Impurity 3 formation during Deucravacitinib synthesis, reducing generation by >40% by adjusting reduction temperature (e.g., 50-60℃) and reaction time.

• Method Validation：Serves as a standard for developing impurity detection methods, verifying UPLC resolution (≥3.0) and LOD (0.01 ng/mL).

Background Description

Deucravacitinib, an oral tyrosine kinase 2 (TYK2) inhibitor, is used for treating autoimmune diseases like psoriasis. Impurity 3, as a process-related impurity of Deucravacitinib, may originate from side products of nitro reduction or amination during triazole ring synthesis. Its amino and triazole groups may affect drug stability and target binding ability. With stricter FDA and EMA requirements for impurities in innovative drugs, studying Impurity 3 is crucial for ensuring drug quality.

Research Status

• Detection Technology：UPLC-MS/MS with C18 column (1.7μm) and 0.1% formic acid-acetonitrile gradient elution achieves separation within 4 minutes, with LOD of 0.005 ng/mL for trace impurity analysis.

• Formation Mechanism：Formed by reduction of 2-methoxy-3-(1-methyl-1H-1,2,4-triazol-5-yl)nitrobenzene under palladium-carbon catalysis; optimizing catalyst dosage and hydrogen pressure inhibits side reactions.

• Safety Evaluation：In vitro cytotoxicity shows IC?? of 192.3 μM against HaCaT cells (Deucravacitinib IC??=11.5 μM), with lower toxicity than the main drug but requiring strict content control. Long-term stability testing is ongoing to monitor degradation under different humidity, light, and temperature conditions.